Impaired verbal episodic memory in healthy older adults is marked by increased F2-Isoprostanes

AuthorsDowney, L.A.
Simpson, T.
Timmer, J.
Nolidin, K.
Croft, K.
Wesnes, K. A.
Scholey, A.
Deleuil, S.
Stough, C.
TypeJournal Article (Original Research)
JournalProstaglandins, Leukotrienes, and Essential Fatty Acids
PubMed ID29482768
Year of Publication2018
URLhttps://www.ncbi.nlm.nih.gov/pubmed/29482768
DOI/10.1016/j.plefa.2018.02.001
AbstractAge-associated cognitive decline amongst otherwise healthy older individuals is a multifaceted characteristic of ageing. The role of oxidative stress biomarkers has been increasingly examined in the context of pathological aging conditions that affect cognition. Plasma F2-Isoprostane levels are a reliable index of systemic oxidative stress (specifically lipid peroxidation) and are elevated in dementia patients. Less is known about their role in healthy cognitive ageing. This study evaluated the relationship between F2-Isoprostanes and cognitive functioning in a cohort of 211 healthy elderly adults (60-75 years: Male; 88, Female; 123). Cognitive assessment included the Cognitive Drug Research (CDR) computerised assessment battery, which produces five validated factor scores (corresponding to 'Quality of Episodic Memory', 'Speed of Memory', Quality of Working Memory', Power of Attention' and 'Continuity of Attention'). Participants with higher F2-Isoprostane levels had significantly lower Quality of Episodic Memory scores (suggesting inferior abilities in retaining and retrieving verbal information in episodic memory). This is, to our knowledge, the first report of compromised verbal episodic memory in healthy ageing humans being linked to increased levels of F2-Isoprostanes. These results have relevance for interventions aimed at improving cognitive performance in the healthy elderly.

http://www.ibas.org.au/what-we-do/publications/3872967


< More publications



CHEST-MND:PROCHEST-MND:PRO

Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....

Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Recognising research meritRECOGNISING RESEARCH MERIT

Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.

Honoring Excellence in ResearchHONORING EXCELLENCE IN RESEARCH

Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.

AMRF Grant Awards for 2025AMRF GRANT AWARDS FOR 2025

Grants Success: The Institute for Breathing and Sleep (IBAS) has received two research grants from the Austin Medical Research Foundation (AMRF) for 2025. Congratulations to Dr Charissa Zaga and Dr Catherine Hill from IBAS.

Recognition by MND AustraliaRECOGNITION BY MND AUSTRALIA

Congratulations to Professor David Berlowitz, Dr Marnie Graco, and Dr Nicole Sheers who were recognised by Motor Neurone Disease (MND) Australia at a Parliament House event sponsored by the Parliamentary Friends of MND in Canberra last week.

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate